Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000661110 | SCV000783358 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-12-15 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Laboratory for Molecular Medicine, |
RCV000508022 | SCV000605758 | pathogenic | Hereditary breast ovarian cancer syndrome | 2017-01-11 | criteria provided, single submitter | clinical testing | The p.Phe697fs variant in BRCA1 has not been previously reported in individuals with hereditary breast and ovarian cancer (HBOC) and was absent from large popul ation studies. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 697 and leads to a prematur e termination codon 4 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of funct ion of the BRCA1 gene is an established disease mechanism in HBOC. In summary, t his variant meets criteria to be classified as pathogenic for HBOC in an autosom al dominant manner. |
Invitae | RCV000508022 | SCV004296835 | pathogenic | Hereditary breast ovarian cancer syndrome | 2022-10-17 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 440454). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 28294317). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe697Serfs*4) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). |